Maged Shenouda, Chief Financial Officer at RELMADA THERAPEUTICS, INC. (RLMD), bought 500,000 shares at $2.20 ($1.1M) on 2025-11-05, disclosed to the SEC on 2025-11-06.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Clearly above the average filing.
| Filing → |
| RLMD | BUY | 2025-05-20 | $97K | — | Filing → |
| RLMD | BUY | 2024-09-11 | $207K | — | Filing → |
| RLMD | BUY | 2024-01-31 | $126K | — | Filing → |